Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome

disease
On this page

Also known as SOLAMEN syndrome

Summary

Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome (MONDO:0015293) is a disease with 1 cohort gene.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 1
  • Phenotypes (HPO): 19

Clinical features

Signs & symptoms

Clinical features (HPO)

19 HPO clinical features (Orphanet curated; top 19 by frequency):

HPO IDTermFrequency
HP:0001482Subcutaneous noduleVery frequent (80-99%)
HP:0005293Venous insufficiencyVery frequent (80-99%)
HP:0007392Excessive wrinkled skinVery frequent (80-99%)
HP:0100026Arteriovenous malformationVery frequent (80-99%)
HP:0100559Lower limb asymmetryVery frequent (80-99%)
HP:0100560Upper limb asymmetryVery frequent (80-99%)
HP:0100761Visceral angiomatosisVery frequent (80-99%)
HP:0100764LymphangiomaVery frequent (80-99%)
HP:0200034PapuleVery frequent (80-99%)
HP:0004349Reduced bone mineral densityFrequent (30-79%)
HP:0010566HamartomaFrequent (30-79%)
HP:0000256MacrocephalyOccasional (5-29%)
HP:0001635Congestive heart failureOccasional (5-29%)
HP:0001883TalipesOccasional (5-29%)
HP:0002757Recurrent fracturesOccasional (5-29%)
HP:0004374Hemiplegia/hemiparesisOccasional (5-29%)
HP:0100013Neoplasm of the breastOccasional (5-29%)
HP:0100031Neoplasm of the thyroid glandOccasional (5-29%)
HP:0100615Ovarian neoplasmOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical namesegmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
Mondo IDMONDO:0015293
Orphanet137608
SNOMED CT763867001
UMLSC4706610
MedGen1637405
GARD0019881
Is cancer (heuristic)no

Also known as: SOLAMEN syndrome

Data availability: 1 ClinVar variant.

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system benign neoplasm › benign neoplasm of skinmelanocytic nevussegmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome

Related subtypes (27): conjunctival nevus, blue nevus, halo nevus, intradermal nevus, pigmented spindle cell nevus, nevus, epidermal, neurocutaneous melanocytosis, neutrophil actin dysfunction, CHILD syndrome, Becker nevus syndrome, CLOVES syndrome, nevus comedonicus syndrome, congenital panfollicular nevus, porokeratotic eccrine ostial and dermal duct nevus, hereditary mucosal leukokeratosis, linear verrucous nevus syndrome, nevus of Ota, nevus of Ito, phakomatosis pigmentokeratotica, PENS syndrome, Angora hair nevus, didymosis aplasticosebacea, scalp syndrome, Nevada syndrome, palpebral nevus, large congenital melanocytic nevus, benign melanocytic skin nevus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
536549NM_000314.8(PTEN):c.801G>T (p.Lys267Asn)PTENPathogenicreviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 14 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
PTENOrphanet:109Bannayan-Riley-Ruvalcaba syndrome
PTENOrphanet:137608Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
PTENOrphanet:145Hereditary breast and/or ovarian cancer syndrome
PTENOrphanet:201Cowden syndrome
PTENOrphanet:210548Macrocephaly-intellectual disability-autism syndrome
PTENOrphanet:2969Proteus-like syndrome
PTENOrphanet:494547Squamous cell carcinoma of the hypopharynx
PTENOrphanet:494550Squamous cell carcinoma of the larynx
PTENOrphanet:500464Squamous cell carcinoma of the nasal cavity and paranasal sinuses
PTENOrphanet:500478Squamous cell carcinoma of the oropharynx
PTENOrphanet:502363Squamous cell carcinoma of the oral cavity
PTENOrphanet:502366Squamous cell carcinoma of the lip
PTENOrphanet:65285Lhermitte-Duclos disease
PTENOrphanet:79076Juvenile polyposis of infancy

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
PTENHGNC:9588ENSG00000171862P60484Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
PTENPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENDual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Phosphatase183.9×0.012

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
PTENPhosphataseyes3.1.3.16Tyr_Pase_dom, Tyr_Pase_cat, Tensin_C2-dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
calcaneal tendon1
endothelial cell1
sperm1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
PTEN256ubiquitousmarkersperm, endothelial cell, calcaneal tendon

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
PTEN11,626

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
PTENP6048412

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
PTEN Loss of Function in Cancer15710.0×0.002PTEN
Regulation of PTEN mRNA translation11142.0×0.004PTEN
Regulation of PTEN localization11038.2×0.004PTEN
Synthesis of IP3 and IP4 in the cytosol1423.0×0.007PTEN
Transcriptional Regulation by MECP21317.2×0.007PTEN
Negative regulation of the PI3K/AKT network1278.5×0.007PTEN
Ovarian tumor domain proteases1278.5×0.007PTEN
Synthesis of PIPs at the plasma membrane1211.5×0.007PTEN
Regulation of PTEN stability and activity1184.2×0.007PTEN
Regulation of PTEN gene transcription1178.4×0.007PTEN
TP53 Regulates Metabolic Genes1129.8×0.008PTEN
Downstream TCR signaling1128.3×0.008PTEN
Ub-specific processing proteases153.1×0.019PTEN

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
negative regulation of synaptic vesicle clustering18426.0×0.002PTEN
negative regulation of keratinocyte migration15617.3×0.002PTEN
rhythmic synaptic transmission14213.0×0.002PTEN
central nervous system myelin maintenance12808.7×0.002PTEN
negative regulation of cell cycle G1/S phase transition12407.4×0.002PTEN
negative regulation of wound healing, spreading of epidermal cells12407.4×0.002PTEN
spindle assembly involved in female meiosis11872.4×0.002PTEN
central nervous system neuron axonogenesis11872.4×0.002PTEN
postsynaptic density assembly11872.4×0.002PTEN
neuron-neuron synaptic transmission11685.2×0.002PTEN
negative regulation of peptidyl-serine phosphorylation11685.2×0.002PTEN
negative regulation of cell size11685.2×0.002PTEN
presynaptic membrane assembly11685.2×0.002PTEN
negative regulation of organ growth11404.3×0.002PTEN
forebrain morphogenesis11404.3×0.002PTEN
multicellular organismal response to stress11296.3×0.002PTEN
negative regulation of axonogenesis11296.3×0.002PTEN
cellular response to electrical stimulus11296.3×0.002PTEN
negative regulation of excitatory postsynaptic potential11296.3×0.002PTEN
maternal behavior11123.5×0.002PTEN
prepulse inhibition11123.5×0.002PTEN
locomotor rhythm11053.2×0.003PTEN
synapse maturation1936.2×0.003PTEN
dendritic spine morphogenesis1887.0×0.003PTEN
negative regulation of focal adhesion assembly1766.0×0.003PTEN
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction1702.2×0.003PTEN
negative regulation of vascular associated smooth muscle cell proliferation1674.1×0.003PTEN
phosphatidylinositol dephosphorylation1648.1×0.003PTEN
positive regulation of intracellular signal transduction1648.1×0.003PTEN
negative regulation of cellular senescence1648.1×0.003PTEN

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
PTEN00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
PTEN8Binding:8

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
PTEN3.1.3.16, 3.1.3.67protein-serine/threonine phosphatase, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug1PTEN
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
PTEN8

Clinical trials & evidence

Clinical trials

Clinical trials: 0.